Author’s Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.
Authors:
- Simone CesaroSimone Cesaro
- Per LjungmanPLPer Ljungman
- Malgorzata MikulskaMMMalgorzata Mikulska
- Hans H. HirschHHHans H. Hirsch
- David NavarroDNDavid Navarro
- Varun MehraVMVarun Mehra
- Jan StyczynskiJSJan Styczynski
- Francesco MarchesiFMFrancesco Marchesi
- Jose Luis PinanaJPJose Luis Pinana
- Gernot BeutelGBGernot Beutel
- Herman EinseleHEHerman Einsele
- 4 August 2025
- journal article
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2304-2305
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper considerationLeukemia, 2025
- Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)Leukemia, 2025
- Convalescent plasma treatment of B-cell depleted patients with COVID-19: systematic review and individual participant data meta-analysismedRxiv, 2025
- Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialEBioMedicine, 2025